← Back to all trials
Completed
NCT07874386
Wearable Tissue Oximetry During Arm Cuff Occlusion, Walking, and Standing Tests in Outpatients With Chronic Heart Failure
Conditions: Heart Failure, Chronic Heart Failure
Sex: All
Ages: 18 Years – 85 Years
Healthy volunteers: No
Enrollment: 50
Sponsor: NIRSense Inc.
Location: Jackson Heart Clinic Jackson Mississippi
Summary
This prospective, single-center, observational pilot study evaluated an investigational wearable tissue oximeter (NIRSense Argus Oximetry System, also called Envello Core) in adult outpatients with chronic heart failure in New York Heart Association (NYHA) class I, II, or III at Jackson Heart Clinic in Jackson, Mississippi. During one routine clinic visit, participants wore three adhesive optical sensors, on the forearm, the thigh, and the sternum, while completing three standard tests: a blood pressure cuff occlusion of the arm (vascular occlusion test), a six-minute walk test, and a change from lying down to standing. The sensors use near-infrared spectroscopy to record changes in tissue oxygenation. The study compared tissue oxygenation responses across NYHA classes and with standard clinical measures (blood pressure, pulse rate, pulse oximetry, and walk distance). Participation added about 30 minutes to the visit, with no follow-up. Fifty participants were enrolled. No treatment decisions were based on the study device.
Eligibility Criteria
Inclusion Criteria:
* Biological males and females between 18 and 85 years old
* Previously diagnosed with heart failure and currently considered a candidate for a diagnosis of Stage 1, Stage 2, or Stage 3 heart failure according to the New York Heart Association (NYHA) classification
* BMI between 18 and 40, with a minimum weight of 40 kg (upper BMI limit raised from 30 to 40 by an IRB-approved administrative change in October 2024)
* Currently able to ambulate independently to the required standards of the 6-minute walk test
Exclusion Criteria:
* Prior known severe allergy to medical-grade adhesive or tape (self-reported)
* Pregnant (self-reported)
* Diagnosed anemia (self-reported)
* History of sickle cell trait or thalassemia (self-reported)
* Diagnosed with Stage 4 heart failure according to the NYHA classification
Source: ClinicalTrials.gov (NCT07874386). StuddyBuddy aggregates publicly available trial information.